Copyright
©2007 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Sep 7, 2007; 13(33): 4458-4466
Published online Sep 7, 2007. doi: 10.3748/wjg.v13.i33.4458
Published online Sep 7, 2007. doi: 10.3748/wjg.v13.i33.4458
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells
Viola Baradari, Michael Höpfner, Alexander Huether, Institute of Physiology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
Detlef Schuppan, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, United States
Hans Scherübl, Klinik für Gastroenterologie und Gastrointestinale Onkologie, Klinikum Am Urban, Vivantes Netzwerk für Gesundheit, Berlin, Germany
Author contributions: All authors contributed equally to the work.
Supported by a scholarship from the Sonnenfeld-Stiftung, Berlin, Germany for Viola Baradari
Correspondence to: Professor Hans Scherübl, Klinik für Gastroenterologie und Gastrointestinale Onkologie, Klinikum Am Urban, Vivantes Netzwerk für Gesundheit, Dieffenbachstrasse 1, 10967 Berlin, Germany. hans.scheruebl@vivantes.de
Telephone: +49-30-69725201 Fax: +49-30-69725205
Received: February 28, 2007
Revised: April 13, 2007
Accepted: April 18, 2007
Published online: September 7, 2007
Revised: April 13, 2007
Accepted: April 18, 2007
Published online: September 7, 2007
Core Tip